全文获取类型
收费全文 | 28915篇 |
免费 | 1809篇 |
国内免费 | 379篇 |
专业分类
耳鼻咽喉 | 238篇 |
儿科学 | 1004篇 |
妇产科学 | 812篇 |
基础医学 | 3272篇 |
口腔科学 | 449篇 |
临床医学 | 4693篇 |
内科学 | 5283篇 |
皮肤病学 | 406篇 |
神经病学 | 2669篇 |
特种医学 | 816篇 |
外科学 | 3053篇 |
综合类 | 313篇 |
一般理论 | 65篇 |
预防医学 | 3956篇 |
眼科学 | 351篇 |
药学 | 1530篇 |
1篇 | |
中国医学 | 38篇 |
肿瘤学 | 2154篇 |
出版年
2023年 | 108篇 |
2022年 | 166篇 |
2021年 | 466篇 |
2020年 | 305篇 |
2019年 | 491篇 |
2018年 | 587篇 |
2017年 | 447篇 |
2016年 | 465篇 |
2015年 | 521篇 |
2014年 | 823篇 |
2013年 | 1399篇 |
2012年 | 1878篇 |
2011年 | 1975篇 |
2010年 | 1104篇 |
2009年 | 1056篇 |
2008年 | 1957篇 |
2007年 | 2110篇 |
2006年 | 2071篇 |
2005年 | 2121篇 |
2004年 | 1999篇 |
2003年 | 1927篇 |
2002年 | 1772篇 |
2001年 | 418篇 |
2000年 | 340篇 |
1999年 | 395篇 |
1998年 | 422篇 |
1997年 | 298篇 |
1996年 | 297篇 |
1995年 | 279篇 |
1994年 | 225篇 |
1993年 | 224篇 |
1992年 | 200篇 |
1991年 | 169篇 |
1990年 | 125篇 |
1989年 | 135篇 |
1988年 | 126篇 |
1987年 | 118篇 |
1986年 | 115篇 |
1985年 | 124篇 |
1984年 | 138篇 |
1983年 | 144篇 |
1982年 | 176篇 |
1981年 | 145篇 |
1980年 | 124篇 |
1979年 | 74篇 |
1978年 | 79篇 |
1977年 | 72篇 |
1976年 | 53篇 |
1975年 | 53篇 |
1974年 | 53篇 |
排序方式: 共有10000条查询结果,搜索用时 3 毫秒
1.
2.
Nancy C. Lee 《Public health reports (Washington, D.C. : 1974)》2015,130(2):121-Apr;130(2):121
3.
4.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
5.
Mhd Wasem Alsabbagh Dana Church Lisa Wenger John Papastergiou Lalitha Raman-Wilms Eric Schneider Nancy Waite 《Research in social & administrative pharmacy》2019,15(2):202-206
Background
One approach to boost influenza vaccination coverage has been to expand immunization authority. In 2012, the province of Ontario gave community pharmacists the authority to administer the influenza vaccine.Objective
This study investigates the perspectives of Ontario pharmacy patrons, who had not recently received this vaccine from a pharmacist, regarding this pharmacist service.Methods
A survey was administered in six Ontario community pharmacies to pharmacy patrons who had not received an influenza vaccination from a pharmacist during the previous year. The instrument included questions about influenza vaccination, and knowledge of and attitudes toward vaccines and pharmacist-administered immunization.Results
A total of 541 pharmacy patrons completed the survey (53.9% response rate). About one-third (30.5%) of respondents were not aware that pharmacists could give the influenza vaccine, with younger individuals being less likely to be aware (OR 0.48, 95% CI 0.29–0.77, p?<?0.05) and less likely to receive the vaccine annually (OR 0.28, 95% CI 0.19–0.42, p?<?0.05). Leading reasons respondents gave as to why they did not receive their influenza vaccine from a pharmacist included not wanting or feeling they needed to be immunized (41.6%) and being used to receiving the vaccine from a physician (16.5%). Concerns about the experience and training of pharmacists and lack of privacy in a community pharmacy were uncommon.Conclusion
Reduced awareness of the availability of pharmacist-provided influenza vaccine is still common. Pharmacists have a significant opportunity to address lack of awareness and vaccine hesitancy issues. They can promote this service to increase influenza vaccination rates among pharmacy patrons who do not utilize this professional service. 相似文献6.
7.
Philip A. Rozario Nancy L. Morrow-Howell Enola K. Proctor 《Quality of life research》2006,15(4):755-759
Using the SF-12 to measure physical and mental functioning, the authors examine the intra-individual changes in health-related
quality of life (HRQOL) 6 months post-discharge for depressed older adults. In addition, they examine three sets of predictors
that might influence these changes. The sample of depressed older adults was recruited from an inpatient geropsychiatry unit.
Although their physical and mental health scores on the SF-12 were lower than comparable norms, the sample showed an average
increase in their mental functioning but a decrease in the physical functioning over the 6 months. Negative life-events were
significant predictors of people who reported no change in their mental health functioning and decreases in their physical
health functioning. Interestingly, those who experienced positive life events were more likely to report declines and younger
participants were more likely to report no change in their physical functioning. The findings indicate that the effects of
depression on HRQOL can have enduring effects on a sample of previously hospitalized older adults. The significance of life
event changes might signify the importance of taking into account non-traditional areas of medical interventions. Further,
the findings indicate the usefulness of the SF-12 quantifying HRQOL outcomes. 相似文献
8.
Andrea DiMartini Nancy Day Mary Amanda Dew Lubna Javed Mary Grace Fitzgerald Ashok Jain John J Fung Paulo Fontes 《Liver transplantation》2006,12(5):813-820
For patients who receive a liver transplant (LTX) for alcoholic liver disease (ALD), investigators are focusing beyond survival to determine specific alcohol use outcomes. Studies suggest the use of alcohol ranges from 8 to 22% for the first post-transplant year with cumulative rates reaching 30 to 40% by 5 years following transplantation. Yet while investigators are interested in determining specific rates of alcohol use and predictors of use, only three studies since 1990 have been prospective. In 1998, we began a prospective study of post-LTX alcohol consumption in ALD recipients using multiple repeated measures of alcohol use. After 5 years of follow-up, we found that 22% had used any alcohol by the first year and 42% had a drink by 5 years. By 5 years, 26% drank at a heavier use (binge) pattern and 20% drank in a frequent pattern. In a univariate model, predictors of alcohol use included pre-transplant length of sobriety, a diagnosis of alcohol dependence, a history of other substance use, and prior alcohol rehabilitation. 相似文献
9.
Severe persistent asthma can have a substantial impact on a patient's health-related quality of life (HRQL), both as a result of symptoms and from side effects of treatment. The HRQL impact of two doses (400 and 800 microg twice daily) of mometasone furoate dry powder inhaler (MF DPI) was compared with placebo in patients with severe persistent asthma previously maintained on oral steroids as a component of a previously published randomized, 12-week, double-blind, placebo-controlled, multicenter trial. A 9-month open-label extension (OLE), with all patients treated with MF DPI, followed. Patients 12 years of age or older completed a generic HRQL measure, the Medical Outcomes Trust Short Form-36 (SF-36), and an asthma-specific measure, the Marks Asthma Quality of Life Questionnaire (AQLQ-M), at baseline, at endpoint (last evaluable visit) of the double-blind phase (EODBP), and after the first 3 months of the OLE. Of 132 patients enrolled in the study, 128 provided HRQL data at baseline and at EODBP. Mean SF-36 scores at baseline showed significant HRQL impairment compared with U.S. general population norms. With treatment, the reduction in oral corticosteroid (OCS) requirements of the MF-DPI-treated groups was accompanied by significant (p < 0.05) improvement over placebo in the physical domain of HRQL (SF-36 physical component summary score and the physical function subscale) at EODBP. MF-DPI-treated patients also showed significant improvements at EODBP in each of the four subscales of the AQLQ-M (p<0.05). From EODBP to the OLE 3-month endpoint, patients treated with MF DPI twice daily maintained, or improved, SF-36 scores in most domains. Symptomatic improvement and reduction in OCS use with MF DPI were accompanied by significant improvement in HRQL in patients with severe persistent asthma. These improvements were maintained during the 3-month period of the OLE in which HRQL was evaluated. 相似文献
10.